Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy

The PD-1/PD-L1 signaling pathway plays a crucial role in cancer immune evasion, and the use of anti-PD-1/PD-L1 antibodies represents a significant milestone in cancer immunotherapy. However, the low response rate observed in unselected patients and the development of therapeutic resistance remain ma...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Tianye Li, Xinrun Wang, Mengke Niu, Mingli Wang, Jianwei Zhou, Kongming Wu, Ming Yi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-07-01
Subjects:	cancer immunotherapy immunotherapy resistance immune checkpoint inhibitor bispecific antibody TGF-β PD-L1
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1196970/full